Skip to search formSkip to main contentSkip to account menu

ASP3026

Known as: ALK Inhibitor ASP3026, ASP-3026 
An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
Receptor Tyrosine Kinase Inhibition

Broader (2)

SulfonesTriazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK… 
Review
2015
Review
2015
Novel ALK inhibitors in clinical use and development
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in… 
2015
2015
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
ALK is involved in the onset of several tumors. Crizotinib (XalkoriTM), a potent ALK inhibitor, represents the current front-line… 
Highly Cited
2015
Highly Cited
2015
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
Introduction: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but… 
Review
2015
Review
2015
The next-generation ALK inhibitors
Purpose of review Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To… 
Highly Cited
2014
Highly Cited
2014
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including… 
2014
2014
The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
NPM-ALK+ T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK+ ALCL is… 
2014
2014
Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
2624^ Background: The efficient early development of agents intended for selected patient populations is challenging. ASP3026 is… 
2013
2013
Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.
2602 Background: ASP3026 (3026) is a selective, potent, ATP-competitive, small molecule oral inhibitor of ALK receptor tyrosine… 
2011
2011
Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -
EML4-ALK is an oncogenic fusion kinase which was first identified in non-small cell lung cancer (NSCLC), and is regarded as an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)